Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 3/20 | 0.47 |
| ▸ | POLQ | O75417 | 2/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 7/20 | 0.42 |
| ▸ | JAK1 | P23458 | 7/20 | 0.42 |
| ▸ | TYK2 | P29597 | 5/20 | 0.42 |
| ▸ | JAK3 | P52333 | 5/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | EIF4EBP1 | Q13541 | 5/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31032111 | 1.00 | F11 (0.47) | F11POLQPTGER1JAK2JAK1 | |
| SCHEMBL24770197 | 0.88 | POLQ (0.48) | F11POLQJAK2JAK1TYK2 | |
| SCHEMBL30017611 | 0.86 | POLQ (0.40) | POLQPTGER1GAA | |
| SCHEMBL24769582 | 0.86 | POLQ (0.40) | POLQPTGER1GAA | |
| SCHEMBL24770095 | 0.85 | POLQ (0.53) | POLQPTGER1GAATSHR | |
| SCHEMBL29695126 | 0.85 | POLQ (0.53) | POLQPTGER1GAATSHR | |
| SCHEMBL24501571 | 0.84 | POLQ (0.45) | POLQGAA | |
| SCHEMBL22717641 | 0.84 | POLQ (0.45) | POLQPTGER1TSHR | |
| SCHEMBL29694629 | 0.84 | POLQ (0.45) | POLQPTGER1TSHR | |
| SCHEMBL29695103 | 0.84 | POLQ (0.45) | POLQPTGER1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122221-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2025-04-17 | — | — | US | disclosed |
| EP-4464709-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2024-11-20 | — | — | EP | disclosed |
| CN-118525025-A | Six-membered cyclothiazole compound and application thereof | 南京再明医药有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-117794927-A | O-linked thiadiazolyl compounds as inhibitors of DNA polymerase theta | 伊迪亚生物科学有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2023134739-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | 南京再明医药有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2022259204-A1 | O-LINKED THIADIAZOLYL COMPOUNDS AS DNA POLYMERASE THETA INHIBITORS | IDEAYA BIOSCIENCES, INC. (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122221-A1 | SIX-MEMBERED CYCLOTHIAZOLE COMPOUND AND USE THEREOF | POLRMT, POLQ, POLH | F11 3416/4885POLQ 2/4885PTGER1 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.